Events Archive 2020

2020

- 22 Dec 2020 – Update on the recently acquired NTCD-M3 programme
- 21 Dec 2020 – Destiny Pharma joins the Pharmabiotic Research Institute (PRI)
- Biotech Showcase conference, 11 – 15 January 2021
- 26 Nov 2020 – Destiny Pharma – Result of General Meeting and Total Voting Rights
- 25 Nov 2020 – Destiny Pharma announces total gross proceeds raised via Open Offer
- 18 Nov 2020 – Antibiotic Resistance: A Matter of Time – FT
- Destiny Pharma to attend Jefferies Virtual London Healthcare conference, 17 – 19 November 2020
- Destiny Pharma is supporting World Antimicrobial Resistance (#AMR) Awareness Week, 18 – 24 November 2020
- 09 Nov 2020 – Destiny Pharma to acquire Phase 3 ready C.difficile program and announces fund raising
- Destiny Pharma to attend EWMA Virtual 2020 conference, 18 – 19 November 2020
- 12 Oct 2020 – Clinical Study Patient Recruitment Update
- 01 Oct 2020 – Destiny Pharma welcomes proposed PASTEUR Act in USA
- 17 Sep 2020 – Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical infections
- 17 Sep 2020 – Interim results for the 6 months ended 30 June 2020
- 10 Sep 2020 – Scrip article “Destiny Pharma and SporeGen back Nasal Spray over Vaccine to tackle COVID-19”
- Destiny Pharma to attend BIO-Europe Digital, 26 – 29 October 2020
- 07 Sep 2020 – Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19
- 17 Aug 2020 – Destiny Pharma welcomes NBIC #BiofilmAware campaign, launched today
- 11 Aug 2020 – Positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections
- 07 Aug 2020 – Could drug-resistant bacteria cause the next pandemic? – Forbes
- 05 Aug 2020 – Neil Clark, CEO, interviewed by Equity Development
- 27 July 2020 – Update on Phase 2b clinical study of XF-73
- 10 July 2020 – Pharma companies join forces to launch $1 billion fund to develop new antibiotics by 2030
- 10 June 2020 – Result of Annual General Meeting
- 09 June 2020 – Grant awarded for Cardiff University collaboration
- 12 May 2020 – Posting of Annual Report and Notice of AGM
- 07 May 2020 – Director of Preclinical Development as panel member for KTN Antimicrobial Resistance Global Expert Mission dissemination seminar
- 06 May 2020 – FT article highlights Coronavirus lessons for the fight against superbugs
- 04 May 2020 – Independent review supports the potential of XF-73
- 29 Apr 2020 – Audited results for the year ended 31 December 2019 and clinical development update
- 08 Apr 2020 – Destiny Pharma featured in Endpoints News
- 02 Apr 2020 – Antibiotic resistance could lead to more covid-19 deaths
- 03 Mar 2020 – Clinical and Business Update
- 21 Feb 2020 – Effectiveness of cancer treatments threatened by rising antibiotic resistance
- Destiny Pharma to attend ECCMID 2020, 18 – 21 April 2020, Paris, France
- Destiny Pharma to attend BIO-Europe Spring, 23 – 25 March 2020, Paris, France
- Destiny Pharma to attend 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics, 12 – 13 March 2020, Basel, Switzerland
- Destiny Pharma to attend Infection Control 2020, 13 February 2020, Birmingham, UK
- Destiny Pharma to attend the 2020 Bioinfect conference, 12th February 2020, Alderley Park, UK
- Destiny Pharma to attend 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics, 12 – 13 March 2020, Basel, Switzerland
- Destiny Pharma to attend Infection Control 2020, 13 February 2020, Birmingham, UK
- 22 Jan 2020 – Proactive interview – Destiny Pharma awaits key inflection point mid-2020 in its antimicrobial Phase 2b clinical trial
- 20 Jan 2020 – Positive update on the development of new XF-platform drug formulations
- Destiny Pharma to present at LSX World Congress 2020, 4th February 2020, London, UK
- Destiny Pharma to present at JPM / Biotech Showcase 2020, 13 – 15 January 2020, San Francisco, USA
- Destiny Pharma to present at LSX World Congress 2020, 4th February 2020, London, UK
- Destiny Pharma to present at BFC Global Healthcare Investment Conference, 12 January 2020, San Francisco, USA